Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_assertion type Assertion NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_head.
- NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_assertion description "[The distinct and favorable expression profile of C35 spanning early through late stages of disease, including high frequency of overexpression in various breast carcinoma, abundant expression in distant metastases, and either absence or low level expression in normal human tissues, warrants further investigation of the relevance of C35 as a biomarker and/or a target for development of broadly applicable cancer-specific therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_provenance.
- NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_assertion evidence source_evidence_literature NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_provenance.
- NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_assertion SIO_000772 17121940 NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_provenance.
- NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_assertion wasDerivedFrom befree-20140225 NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_provenance.
- NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_assertion wasGeneratedBy ECO_0000203 NP424332.RA4EAGEXPey57G_6I72xbXh3kb-NnOmnvWRFB00N-t6X4130_provenance.